Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Inmaculada Ramos García, Byoung Chul Cho et al.|The Lancet Oncology|2018Cited by 579
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette Ma, Anthony T.�C. Chan, Nathan R. Foster et al.|Journal of Clinical Oncology|2018Cited by 473
Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinomaJason Yongsheng Chan, Alex Y. Chang, Abner Herbert Lim et al.|Liver Cancer International|2020Cited by 7